Zanerva Capsules

Zanerva Capsules

S5
PDF Leaflet Revision Date: 29 May 2023

API: Pregabalin | Company: Forrester Pharma

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of neuropathic pain due to Herpes zoster and diabetes.

Dosage (summary)

Starting dose: 75 mg twice daily; may increase to 150 mg twice daily.

Special Populations

  • Renal impairment
  • Hepatic impairment
  • Elderly patients

Pregnancy & Breastfeeding

Not recommended during pregnancy; unknown if excreted in breast milk.

Key Drug Interactions

  • CNS depressants may enhance effects
  • Antidepressants may cause respiratory failure

Contraindications

  • Hypersensitivity to pregabalin

Common side effects

  • Dizziness
  • Somnolence
  • Weight gain
  • Blurred vision

Counselling Points

  • Monitor for signs of suicidal ideation
  • Avoid driving until effects are known
  • Gradual discontinuation recommended

Serious warnings

  • Severe cutaneous adverse reactions
  • Risk of respiratory depression
  • Potential for misuse and dependence
Important Disclaimer

The Zanerva Capsules professional information leaflet below is the property of Forrester Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites